Cancer drug developer Immunomedics (NASDAQ: [[ticker:IMMU]]) announced that Robert Iannone, who has held the chief medical officer for post for a little more than one year, is leaving to pursue work closer to his Pennsylvania home. In a securities filing, Morris Plains, NJ-based Immunomedics said the timing of Iannone’s departure and additional transitional details are still being discussed. Iannone will become the second Immunomedics executive to leave this year. In February, then-CEO Michael Pehl said he would resign, an announcement that came a month after the FDA rejected Immunomedics triple negative breast cancer drug sacitizumab govitecan due to manufacturing problems.
